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A B S T R A C T
Triple negative breast cancer (TNBC) represents the 15–20% of all breast cancers (BC) and is characterized by a
very aggressive behavior. Recent data suggest that TNBC is not a single disease, but it is rather an umbrella for
diﬀerent ontology-proﬁles such as basal like 1 and 2, mesenchymal, and the luminal androgen receptor (LAR).
The LAR subtype is characterized by the expression of the Androgen Receptor (AR) and its downstream eﬀects.
Notwithstanding the role of the AR in several signaling pathways, its impact on a biological and clinical
standpoint is still controversial. The LAR subtype has been associated with better prognosis, less chemotherapy
responsiveness and lower pathologic complete response after neoadjuvant treatment. Clinical evidence suggests
a role for anti-androgen therapies such as bicalutamide, enzalutamide and abiraterone, oﬀering an interesting
chemo-free alternative for chemo-unresponsive patients, and therefore potentially shifting current treatment
strategies.
Introduction
Androgen receptor (AR) is a steroid hormonal receptor that belongs
to the nuclear receptors family together with estrogen (ER), gluco-
corticoid, progesterone (PR) and mineralcorticoid receptor. It links a
transcription factor that controls speciﬁc genes involved in diﬀerent,
sometimes opposite, cellular processes: it can stimulate or suppress
both cell proliferation and apoptosis, depending on the concurrent
signaling pathways activated [1–6]. Androgen receptor is expressed in
about 70–90% of breast cancers and its expression varies from 10% to
50% in triple negative breast cancer (TNBC) [7–11].
AR seems to play a major role in TNBC carcinogenesis. However, its
impact on patient prognosis and its predictive role in patients with
TNBC are still controversial. The present review focuses on AR biology
and covers the current clinical evidences on both predictive and prog-
nostic implications of AR in TNBC.
The biological role of AR
The AR gene is located on chromosome Xq11-12 and encodes for a
110 kDa cytoplasmic polypeptide comprising four distinct functional
regions: a N-terminal region involved in transcriptional activation, a
regulatory domain at the amino terminal (AF-1 site), a DNA binding
domain composed of two zinc ﬁngers, a hinge region with a nuclear
localization signal and a C-terminal ligand-binding domain (AF-2 site)
(Fig. 1) [12]. The role of AR in breast cancer carcinogenesis is complex.
Without its ligand, AR is found in the cytoplasm kept inactive by a
heterocomplex with heat-shock proteins and a chaperone complex
(HSP-70, HSP-90). Circulating androgens bind to the C-terminal ligand-
binding domain leading to a conformational change which allows AR
dimerization. After ligand binding, receptor-hormone complex trans-
locates into the nucleus where it promotes a co-activator-mediated
transcription of target genes (transcriptional/genomic modality of AR
activation), and an inactivation of AR transcription through a negative
feed-back [1,13].
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However, AR can also be activated through a non-transcriptional/
non-genomic mechanism that does not need DNA or RNA interaction
and that modulates AR activity by signal transduction in an ERK-de-
pendent or -independent manner. ERK-mediated AR signaling involves
cytoplasmic AR which interacts with phosphoinositide 3-kinase (PI3K),
Src proteins and Ras GTPase. Non ERK-mediated AR signaling may
involve the mammalian target of rapamycin (mTOR) phosphorylation,
the forkhead box protein O1 (FOXO1) inactivation, and the protein
kinase A (PKA) activation and results in increased cell proliferation
(Fig. 2) [6,14].
AR and cell signal transduction pathways
AR enriched TNBC cell lines frequently carry PI3KCA mutations
which make them very sensitive to PI3K/mTOR inhibition. The cross-
talk between these two pathways have been suggested to promote
cancer cell growth [15,16]. Additionally, AR phosphorylation via
phosphorylated AKT abolishes AR-induced apoptosis resulting in in-
creased cell survival [17,18]. AR expression may also up-regulate
PTEN, due to more frequent mutations of AR in the kinase domain
(exon 20), than in the catalytic domain (exon 9) which leads to an in-
crease in PTEN levels [19]. It has been observed that AR expression in
ER-negative MDA-MB-453 cells induces PTEN which represses PI3KCA
activation and reduces AR activity [20]. At the same time, PTEN acts
with the protein killin (KLLN) and induces p53 and p73, resulting in
increased apoptosis. These preclinical data explain the anti-pro-
liferative eﬀect of AR that could cause the favorable prognosis in terms
of DFS and OS seen among AR-positive TNBC patients [21–23].
GATA-3, a transcription factor involved in mammary gland devel-
opment and its luminal cell diﬀerentiation also seems to interact with
AR. It has been demonstrated that GATA-3 may limit the response to
chemotherapy by activating the downstream targets of ER signaling,
even in ER negative breast cancers, probably under the inﬂuence of the
AR. Indeed, Naderi at al. found that the activation of AR in ER negative
cells induced the expression of FOX1A, which is a downstream target of
GATA-3 itself [24]. It was also demonstrated that GATA-3 expression
was strongly correlated with AR-positivity especially in apocrine TNBCs
[24,25].
Moreover, gene microarray and ChIP-seq analysis showed that AR-
positive TNBC presents an up-regulation of the EGFR ligand amphir-
egulin, involved in tumor proliferation mediated by the EGFR signaling
pathway. Enzalutamide seems to decrease this eﬀect in cell lines ex-
pressing AR [16].
AR and epithelial-to-mesenchymal transition
Recently, the zinc-ﬁnger enhancer binding protein (ZEB1) tran-
scription factor, has been associated with AR positive TNBC subtypes.
ZEB1 activation has been associated to an Epithelial to Mesenchymal
Transition (EMT) phenotype and predicts for poor patient survival due
to a higher metastatic potential [26]. In TNBC, the ZEB1 - AR cross-talk
is probably due to a direct binding of ZEB1 to the E-box sequence on the
AR promoter [27]. Interestingly, a morphological switch from a me-
senchymal to epithelial phenotype was observed after ZEB1 knockdown
in TNBC cell lines. ZEB1 suppression in TNBC cell lines was also asso-
ciated with a decrease of AR mRNA and AR downstream targets and a
sensitization to bicalutamide. Consistently, the treatment with bicalu-
tamide reduced the expression of ZEB1 in treated cells [26,28–30].
AR plays a critical role in cancer metastasis development also by
promoting migration and invasion, through the extracellular matrix
degradation. Preclinical models have demonstrated that AR induces the
expression of metalloproteinase (MMP), in particular, MMP2 and
MMP9 [31]. The decreased anchorage-independent growth and inva-
sion, and the increased apoptosis reported in clinical trials with en-
zalutamide in AR-positive TNBC subtypes, including mesenchymal
stem-like, mesenchymal-like and basal-like, further support this hy-
pothesis [32].
AR and cell cycle regulators
Noteworthy, AR interacts also with cell cycle regulators and BC
susceptibility genes such as Poly-ADP-ribose-polymerase 1 (PARP1) and
BRCA1. BRCA1 plays a key role in double-strand breaks repair when a
DNA damage occurs, while PARP1 is important in the base excision
repair process for DNA single-strand breaks repair. It has been recently
reported that BRCA1 and PARP1 act as coactivators of AR and promote
AR-targeted gene transcription. Preclinical evidences suggest that
PARP1 inhibitors in AR positive TNBC reduce cell migration and
Fig. 1. Androgen receptor gene. Androgen receptor gene is mapped to the long arm of X chromosome (Xq11-12). The androgen receptor protein is encoded by 8
exons (1–8) separated by introns up to 26 Kb in size 8. The protein is composed by distinct functional regions. The exon 1 encoded the N-terminal region (NTD), exons
2 and 3 encoded a DNA binding domain (DBD). The 5′ region of exon 4 encoded for a hinge region, while the 3′ region of exon 4–8 encoded a ligand binding domain
(LBD).
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invasion, thereby preventing DNA repair as well as reducing AR ac-
tivity. This implies an important role of AR in BRCA1-dependent tumor
suppression. Furthermore, BRCA1-mutated BC show a lower expression
of AR and preclinical studies have highlighted an increased apoptosis
when PARP1 inhibitors were combined with AR inhibitors. However,
further studies are required to clarify the crosstalk and the role of these
pathways in TNBC cells [22,33,34].
AR, angiogenesis and immune system
Recently, it was observed that AR pathway could be inﬂuenced by
the hypoxia-inducible factor 1 alfa (HIF-1a) and the vascular en-
dothelial growth factor (VEGF). Preclinical evidence show that the
treatment with dutasteride, a dual blocker of both the type-1 and type-2
isoform of the steroid-5 alfa-reductase (SRD5A1), was associated with a
reduction in protein expression of VEGF and HIF-1a, resulting in an
increased chemosensitivity, and dose- dependent decrease in cell via-
bility of about 40% [35]. If conﬁrmed in clinical prospective trials it
could be used in combination with chemotherapy in the treatment of
this subgroup of TNBC. Even though nowadays less investigated, the
crosstalk between AR and the immune system is not less important.
Indeed, treatment with AR inhibitors may increase the recruitment of
cytotoxic T cell, which could enhance susceptibility to immunotherapy
[15,31].
Genomic proﬁling in TNBC and AR expression
Molecular characteristics of the main gene ontology-based proﬁles
Genomic proﬁling strategies have been explored to shed light on the
deep heterogeneity which characterize TNBC. The IHC-deﬁned TNBC
proﬁle is actually composed by a wide range of molecular proﬁles that
show profoundly diﬀerent gene ontologies.
In 2011, Lehmann et al. reported six molecular subtypes of TNBC
each characterized by potentially new therapeutic targets: 2 basal like
classes (BL1 and BL2), an immunomodulatory (IM), a mesenchymal
Fig. 2. Androgen receptor activation. Androgen receptor resides in the cytoplasm in an inactive form through a heterocomplex with heat-shock proteins and a
chaperone complex (HSP-70, HSP-90). Hormone binding induces a conformational change which allows AR activation. Transcriptional/genomic modality of AR
activation: receptor-hormone complex translocates into the nucleus and interacts with co-activators, co-repressor and transcription modulators. As a result, it
promotes the transcription of target genes. Non-transcriptional/non-genomic modality of AR activation: ERK-mediated AR signaling involves phosphoinositide 3-
kinase (PI3K), Src proteins and Ras GTPase. Non ERK-mediated AR signaling involves the mammalian target of rapamycin (mTOR) phosphorylation, the forkhead box
protein O1 (FOXO1) inactivation, and the protein kinase A (PKA) activation.
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(M), a mesenchymal stem cell (MSL) and the luminal androgen receptor
(LAR) class, characterized by AR expression (Fig. 3A) [36,37].
The recently reﬁned version of TNBC molecular classiﬁcation de-
ﬁned four main subtypes, BL1 and BL2, M, and LAR, with unique
ontologies and diﬀerential response to therapy [38] (Fig. 3B). Biolo-
gical pathways involving cell cycle control, DNA damage response and
high cell proliferation characterize the BL1 proﬁle. These tumors
respond to antimitotic agents such as platinum salts and PARP in-
hibitors. The BL2 subtype is characterized by the expression of EGFR,
TP63, MET and activation of glycolysis and gluconeogenesis pathways.
The M group includes more than half of the metaplastic carcinomas and
is characterized by EMT and frequent PIK3CA mutations or PTEN de-
ﬁciency. These tumors respond to tyrosine kinase (TKI) and mTOR in-
hibitors. Interestingly, eribulin mesylate could be particularly
Fig. 3. A and B. Lehmann classiﬁcation 2011 and 2016. (A) Triple negative breast cancer (TNBC) was classiﬁed into main six subgroups: two basal like classes
(BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem cell (MSL) and the luminal androgen receptor (LAR) class. (B) Triple negative
breast cancer (TNBC) was classiﬁed into main six subgroups: two basal like classes (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal
stem cell (MSL) and the luminal androgen receptor (LAR) class.
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beneﬁcial in this subtype since it is capable to suppress EMT. Notably,
although AR mainly characterizes the LAR proﬁle, it seems to play an
important role also in non-LAR subtypes, such as M, BL1 and BL2
[15,32,39]. The LAR subtype is closely linked to histological apocrine
type tumors and was so termed because it can be deﬁned as TNBC by
IHC but histologically and genetically is similar to ER-positive BC. Gene
ontologies deﬁning the LAR subtype are enriched in hormonally regu-
lated pathways including steroid synthesis and androgen/estrogen
metabolism [37]. Because of this, phase II and III clinical trials reported
encouraging results in term of clinical beneﬁt after treatment with both
bicalutamide and enzalutamide among patients with AR-positive TNBC
[40,41]. PI3K inhibitors in addition to an AR antagonist seems to be
more eﬀective in treating AR-positive TNBC because PIK3CA mutations
are frequently activated in these tumors. Further studies testing the
clinical eﬀect of concurrent treatment of PI3K inhibitors and AR
blockades are ongoing [5,36].
LAR TNBC have lower proliferation rates compared to the other
TNBC subtypes, resulting in a partial chemoresistance; consistently, a
retrospective analysis of 130 patients treated with neoadjuvant che-
motherapy has shown a lower pCR rate in LAR (10%) in respect to BL1
tumors (52%) [42].
Among the diﬀerent gene ontology-based classiﬁcation systems, the
LAR deﬁnition seems one of the most solid. A newly published classi-
ﬁcation system based on both RNA and DNA proﬁling, identiﬁed 4
molecularly deﬁned TNBC subtypes: LAR, Mesenchymal (MES), Basal-
Like Immune-Suppressed (BLIS), and Basal-Like Immune-Activated
(BLIA), characterized by diﬀerent prognosis and potential therapeutic
targets [43]. Interestingly, DNA analysis highlighted proﬁle-speciﬁc
gene ampliﬁcations and targetable molecular expression. LAR was
found to be particularly characterized by both AR and MUC1 markers,
remarking the strategic importance of anti-AR therapy but also the
potential role of MUC1 vaccines as an eﬀective treatment for this sub-
type. Interestingly, in contrast with other proﬁles, LAR subtype iden-
tiﬁed by this new classiﬁcation system share the same genetic and
biologic characteristics of those identiﬁed by Lehmann/Pietenpol el al
[37,43].
New approaches and future applications
New, alternative, approaches have been explored to enable trans-
ferability of molecular proﬁling to the clinic.
A recently published transcriptome analysis identiﬁed 4 distinct
TNBC clusters according to RNA expression. Among these, the LAR
cluster was characterized by gene ontology enriched in hormone-de-
pendent pathways. Spearman’s correlation analysis highlighted a sig-
niﬁcant association between the LAR subtype deﬁned according to the
Lehmann/Pietenpol classiﬁcation and the LAR cluster identiﬁed by the
transcriptome-driven proﬁles. In detail, an upregulated estrogen de-
pendent signaling pathway was highlighted in the LAR cluster deﬁned
by RNA analyses, conﬁrming the pivotal role of the anti-androgen
therapy but also suggesting a potential impact of traditional anti-es-
trogen therapies [44].
Recently, some eﬀorts have been made to integrate gene-expression
proﬁles with MicroRNAs (miRNAs) expression levels [45]. miRNAs are
short non-coding RNAs that regulate the function of target genes at the
post-transcriptional phase and are involved in cancer progression and
metastasis. In particular, miR-363 seem to be a promising target, but
results are still limited [46].
Parker et al. developed a treatment-focused approach based on
Next-Gen RNA-sequencing analysis using a “from bedside back to
bench” strategy. An initial training set was built by analyzing 80 sam-
ples of patients treated with enzalutamide and 42 from untreated pa-
tients and was used as a basis to develop a gene expression model of
biological subtype according to treatment response. This new approach
was capable to predict a 16-weeks clinical beneﬁt from enzalutamide
and therefore better identify androgen-sensitive tumors among TNBC
with a 80% sensitivity and 65% speciﬁcity [47].
Prognostic implications of AR in TNBC
The prognostic impact of AR among TNBC patients is controversial.
Several studies have highlighted the favorable prognosis of LAR TNBC
given the lower Ki-67 and mitotic index and the lower tumor grade and
clinical stage at diagnoses [20,48,49]. In detail, a recent meta-analysis
by Wang et al. analyzed data from 2826 women with TNBC from 13
trials conducted between 2007 and 2015 and showed that AR, ex-
pressed in the 24.4% of the overall TNBC study cohort, was sig-
niﬁcantly associated with post-menopausal status (26.9% of patients
with AR expressing tumors were postmenopausal and 13.4% were pre-
menopausal), low tumor grade (40.8% of patients with AR expressing
tumors were G1-2 and 23% were G3) and with a high risk of nodal
involvement (28.8% of patients with AR expressing tumors were node
positive and the 22.6% were node negative) [50]. Consistently, Maeda
et al. reported an association between AR and both low clinical stage
and nuclear grade, among 23 patients with TNBC and Gasparini et al
showed that high grade TNBC presented lower AR expression
(p < 0.01) [48,49]. In a cohort of 203 asian patients, AR positive
TNBC showed a lower Ki67 proliferation index [51,52].
Sutton and al. suggested a higher incidence of distant metastases in
AR-negative tumors [51,52]. A single study exploring the prevalence of
AR expression in 88 patients with inﬂammatory breast cancer (IBC)
showed that only 5 of the 17 TNBC were AR-positive. Interestingly,
women with AR-negative TNBC had inferior 5-year survival rates
compared with the AR-positive TNBC and the other histologic sub-
groups (p < 0.03) [53].
Three recent meta-analyses have shown longer disease-free survival
(DFS) in AR-positive versus AR-negative breast cancer patients. In de-
tail, Qu et al reviewed 12 studies including 5270 patients with breast
cancer. The overall rate of AR expression in these studies was 65.2%.
The combined hazard ratio (HR) of DFS for all 12 eligible studies was
0.52 (95% CI 0.43–0.64), suggesting that AR expression in breast tu-
mors was an indicator of low risk of recurrence. The HR of overall
survival (OS) for all studies was 0.66, but it was not statistically sig-
niﬁcant [54]. Similarly, Kim et al. selected 16 articles published be-
tween 1992 and 2013. With DFS data available for 521 TNBC patients,
AR-positive tumors had a signiﬁcant lower risk of relapse compared to
the other TNBC subgroups (OR for DFS 0.44, p 0.002) [55]. Finally, an
additional meta-analysis by Wang et al. conﬁrmed that women with
AR-positive TNBC display a 20% lower risk of recurrence compared
with AR-negative TNBC (HR 0.8, p < 0.05). While DFS ﬁndings in all
these analyses were concordant, both Qu and Wang found no associa-
tion between AR status and overall survival, whereas the study by Kim
et al. showed an overall survival beneﬁt for AR-positive TNBC patients
(OR 0.26, p 0.001) [50,54,55]. Results of a recent prospective study by
Asano et al corroborate these latest ﬁndings as 59 of 190 TNBC patients
(29.5%) who displayed AR-positive status had a signiﬁcantly favorable
Cancer Speciﬁc Survival (p= 0.0034) [56]. In summary, despite initial
studies suggested a potential negative prognostic role for AR in TNBC
[57–60], a growing body of evidences indicates that AR expression is
associated with a favorable prognosis. Data concerning OS are still
weak and will need further prospective studies.
Predictive value of AR in TNBC
Despite its clinical aggressive behavior, TNBC is commonly con-
sidered more sensitive to chemotherapy compared to others histological
subtypes given the higher expression of proliferation-related genes in
this subgroup of BC [59]. However, the molecular tumor features as-
sociated with LAR TNBC may result in a less responsive phenotype to
chemotherapy.
Several studies, particularly in the neoadjuvant setting [16,42],
have investigated whether AR positivity is a chemo-resistance marker
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in TNBC. Using samples from patients enrolled in the GeparTrio phase
III neo-adjuvant trial, Loibl et al evaluated AR expression and its impact
on outcome [60]. Overall, 637 core biopsies from primary breast cancer
patients treated with neoadjuvant docetaxel/doxorubicin/cyclopho-
sphamide (TAC) chemotherapy were analyzed and AR was detected in
53.2% of tumors. In AR-positive tumors, pathological complete re-
sponse (pCR) rate was 12.8% compared to 25.4% in AR-negative tu-
mors (P < 0.0001). Among the TNBC subgroup AR expression pre-
dicted a better DFS (AR-positive 85.7% vs. AR-negative 65.5% log-rank
P=0.0544) and OS (95.2% vs. 76.2%; log-rank P= 0.0355). Within
the non-pCR subgroup, AR positivity selected a group with a signiﬁcant
better DFS (P=0.045) and OS (0.021) but not within the pCR group
[60]. Masuda et al. retrospectively classiﬁed 146 TNBC tumors ac-
cording to their gene expression proﬁle and found that LAR tumors had
a lower pCR rate as none of the 20 LAR patients achieved pCR after neo-
adjuvant chemotherapy [42]. Similarly, pCR was signiﬁcantly less fre-
quent in AR-positive compared with AR-negative TNBC in a prospective
trial conducted on 117 Japanese women [56]. Recently, a study in-
vestigating the eﬃcacy of neoadjuvant cisplatin plus paclitaxel with or
without everolimus in 145 TNBC patients, demonstrated that low levels
of AR expression (< 10%) were more likely to be associated with pCR
than higher AR levels. These ﬁndings were consistent in both control
and experimental arm. Interestingly, authors observed no signiﬁcant
modiﬁcations in AR levels in serial samples, obtained before, during
and after the treatment, suggesting that AR expression is not aﬀected by
chemotherapy. Taken together, these results seem to suggest a negative
predictive role of AR in the neo-adjuvant chemotherapy setting, being
AR positivity correlated with a lower pCR rate. Nonetheless, women
displaying an AR positive TNBC had a better DFS and OS, indicating
that in LAR pCR may not be an appropriate surrogate marker of sur-
vival. Testing AR status at diagnosis could lead to a better selection of
patients who are likely to beneﬁt from a more aggressive neo-adjuvant
treatment. New therapeutic strategies, such are the combination of
chemotherapy with an anti-androgen (i.e. NCT02689427), could lead to
a de-esclation of chemotherapy in this subtype.
Notably, AR expression seems to reduce TNBC radiosensitivity too,
although preliminary evidence suggests that bicalutamide might restore
the eﬀect of therapeutically directed ionizing radiation in these patients
[61]. More studies are required to further conﬁrm these ﬁndings.
In addition, other markers have been explored in order to further
reﬁne AR’s predictive potential, such as GATA-3 in the neoadjuvant
setting or CK5/6 and p53 [46,62,63].
Androgen receptor as a therapeutic target in TNBC: Clinical
evidence
The ﬁrst clinical trial reporting activity of antiandrogen therapy in
advanced breast cancer was published by Gucalp et al in 2013 and
conducted by the Translational Breast Cancer Research Consortium
(TBCRC). It was an open-label, single-arm study testing the AR an-
tagonist bicalutamide at the dose of 150mg administered orally on a
continuous daily schedule, for the treatment of women with metastatic
AR-positive TNBC. Primary endpoint was the clinical beneﬁt rate (CBR)
deﬁned as the total number of patients who show a complete response
(CR), partial response (PR), or stable disease (SD) > 6months, while
secondary endpoints were progression-free survival (PFS), safety and
toxicity. Twenty-six patients were evaluable for the primary endpoint
out of the 452 screened [40] (Table 1). Clinical beneﬁt rate was 19%
with a median PFS of 12 weeks (range 6.25–57.5 months), giving a
proof of concept of the potential clinical role of targeting AR in TNBC
treatment. Overall, the treatment was well tolerated and the most
common treatment-related adverse events (AEs) were fatigue, hot ﬂa-
shes, limb edema, and elevation of liver function tests.
Data from a phase II trial evaluating a new generation AR antago-
nist, enzalutamide, in AR positive TNBC, were presented at the 2015
ASCO meeting [61]. Primary endpoint of the trial was CBR deﬁned as
CR plus PR plus SD at 16 weeks (Table 1). CBR at 24 weeks, response
rate (RR) and safety were evaluated as well. As in the Gucalp study,
evaluable patients were deﬁned as having AR IHC≥ 10% and a re-
sponse assessment. Outcomes were evaluated according to an an-
drogen-driven gene signature (Dx). Out of the 404 samples tested for
AR IHC, 79% had AR > 0% and 55% had at least AR=10%, sug-
gesting a higher AR prevalence than previously reported. Among the 75
evaluable patients, this trial showed a CBR at 16 and 24weeks of 35%
and 29%, respectively. Median PFS was higher in Dx-positive patients
(32 vs 9 weeks), two CR and 5 PR were reported. The most frequent
adverse events were fatigue, decreased appetite and nausea.
Another phase II trial tested the potential role of abiraterone, given
the mechanism of action of this drug as selective inhibitor of CYP17
[61] (Table 1). Abiraterone was administered orally on a continuous
daily schedule at the dose of 1000mg in heavily pretreated women with
AR-positive TNBC, adding ﬁve milligrams of prednisone twice a day to
avoid adverse eﬀects correlated to increased mineralocorticoid levels.
Primary endpoint of the study was CBR at 6months. Objective response
rate, duration of response, PFS and safety were secondary endpoints.
Starting from 146 patients screened, 30 patients were considered eli-
gible. Overall, 6 patients showed a clinical beneﬁt at 6 months (20%),
with CR in 1 patients and SD more than 6months in 5 patients and an
objective response rate of 6.7%. Median PFS was 2.8 months. Fatigue,
hypertension, hypokalemia and nausea were the most common adverse
events, predominantly grade 1 and 2. Two patients had a treatment-
related serious adverse event, 1 with grade 3 hypokalemia and the other
with grade 3 adrenal insuﬃciency [62].
An ongoing trial presented at ASCO 2016, is currently evaluating
the combination of bicalutamide and palbociclib: preliminary phar-
macokinetic results showed a good safety proﬁle, while eﬃcacy data
have yet to be released (Table 1) [63]. Several clinical trials are cur-
rently ongoing in both the (neo)-adjuvant (NCT02689427;
NCT01889238) and the metastatic settings (NCT01889238) testing
enzalutamide alone and in combination with other drugs (Table 2).
Moreover, the PI3K/mTOR pathway has been explored in order to
enhance anti-AR endocrine therapy, similarly to the ER targeted
strategy. Preclinical evidence showed that AR-positive TNBC cell lines
are sensitive to PI3K/mTOR inhibitors in association with bicalutamide.
An additional study found that the combination of the mTOR inhibitor
Rapamycin and Enzalutamide has anti-proliferative eﬀects against LAR
xenograft models in mice [64]. Recently a combination of taselisib
(PI3Kα inhibitor) and Enzalutamide was launched, but recruitment has
been suspended (NCT02457910) (Table 1).
Conclusion
The AR is an emerging and promising therapeutic target in breast
cancer and, in particular, in the TNBC subtype, both because of the lack
of a well-established targetable feature and the presence of a solid
molecular subtype with diﬀerent prognosis and clinical behavior.
Notwithstanding the eﬀectiveness of an endocrine therapy-based
Table 1
Antiandrogen therapy in LAR-TNBC: clinical trials.
N Treatment CBR CI
Gucalp et al.
[40]
452 Bicalutamide 150mg continuous daily
schedule
19% 95%
Traina et al.
[41]
118 Enzalutamide 160mg continuous daily
schedule
35% 95%
Bonnefoi
et al.
[62]
30 Abiraterone 1000mg+prednisone
5mg twice/day continuous daily
schedule
20% 95%
Gucalp et al.
[63]
33 Bicalutamide 100mg continuous daily
schedule+Palbociclib 100mg daily
3 weeks on 1 week oﬀ
Ongoing
analysis
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strategy, which could enhance both outcome and quality of life, ex-
ploiting the interlink between AR and EMT could be a potentially new
approach in the treatment of this subtype.
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